Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication

摘要: Background: The aim was to investigate the effect of ramipril on clinical parameters in patients with peripheral arterial disease. Methods: Patients intermittent claudication were randomized receive or placebo for 24 weeks a double-blind study. Outcome measures walking distance, stiffness measurement and quality life (QoL). Results: A total 33 included (25 men; mean(s.d.) age 64·6(7.8) years); 14 received 19 placebo. After 24 weeks, improved maximum treadmill distance by an adjusted mean (95 per cent confidence interval, c.i.) 131 (62 199) m (P = 0·001), 122 (56 188) m 0·001) patient-reported 159 (66 313) m 0·043) compared Ramipril reduced carotid femoral pulse wave velocity –1·47 c.i. –2·40 –0·57) m/s (P = 0·002). Resting ankle : brachial pressure index (ABPI) slightly both groups (0·02 –0·08 0·11) versus 0·03 (–0·05 0·10); P 0·830). had slight, non-significant QoL physical domains placebo. Conclusion: claudication; however, this improvement not related ABPI but might have been due reducing stiffness. Registration number: NCT01037530 (http://www.clinicaltrials.gov).